Dengue Reporter Virus Particles for Measuring Neutralizing Antibodies Against Each of the Four Dengue Serotypes

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2011 Nov 19

PMID 22096543

Citations 50

Authors

Kimberly Mattia

Bridget A Puffer

Katherine L Williams

Ritela Gonzalez

Meredith Murray

Emily Sluzas

Dan Pagano

Sandya Ajith

Megan Bower

Eli Berdougo

Eva Harris

Benjamin J Doranz

Affiliations

Soon will be listed here.

Abstract

The lack of reliable, high-throughput tools for characterizing anti-dengue virus (DENV) antibodies in large numbers of serum samples has been an obstacle in understanding the impact of neutralizing antibodies on disease progression and vaccine efficacy. A reporter system using pseudoinfectious DENV reporter virus particles (RVPs) was previously developed by others to facilitate the genetic manipulation and biological characterization of DENV virions. In the current study, we demonstrate the diagnostic utility of DENV RVPs for measuring neutralizing antibodies in human serum samples against all four DENV serotypes, with attention to the suitability of DENV RVPs for large-scale, long-term studies. DENV RVPs used against human sera yielded serotype-specific responses and reproducible neutralization titers that were in statistical agreement with Plaque Reduction Neutralization Test (PRNT) results. DENV RVPs were also used to measure neutralization titers against the four DENV serotypes in a panel of human sera from a clinical study of dengue patients. The high-throughput capability, stability, rapidity, and reproducibility of assays using DENV RVPs offer advantages for detecting immune responses that can be applied to large-scale clinical studies of DENV infection and vaccination.

Citing Articles

Functional genomics screens reveal a role for TBC1D24 and SV2B in antibody-dependent enhancement of dengue virus infection.

Belmont L, Contreras M, Cartwright-Acar C, Marceau C, Agrawal A, Levoir L J Virol. 2024; 98(11):e0158224.

PMID: 39377586 PMC: 11578089. DOI: 10.1128/jvi.01582-24.

Simultaneous quantitation of neutralizing antibodies against all four dengue virus serotypes using optimized reporter virus particles.

Lingemann M, Amaro-Carambot E, Lamirande E, Pierson T, Whitehead S J Virol. 2024; 98(7):e0068124.

PMID: 38953379 PMC: 11265411. DOI: 10.1128/jvi.00681-24.

Functional genomics screens reveal a role for TBC1D24 and SV2B in antibody-dependent enhancement of dengue virus infection.

Belmont L, Contreras M, Cartwright-Acar C, Marceau C, Agrawal A, Levoir L bioRxiv. 2024; .

PMID: 38712102 PMC: 11071485. DOI: 10.1101/2024.04.26.591029.

Single B cell transcriptomics identifies multiple isotypes of broadly neutralizing antibodies against flaviviruses.

Lubow J, Levoir L, Ralph D, Belmont L, Contreras M, Cartwright-Acar C PLoS Pathog. 2023; 19(10):e1011722.

PMID: 37812640 PMC: 10586629. DOI: 10.1371/journal.ppat.1011722.

Pseudotyped Viruses.

Wang Y, Zhou Z, Wu X, Li T, Wu J, Cai M Adv Exp Med Biol. 2023; 1407:1-27.

PMID: 36920689 DOI: 10.1007/978-981-99-0113-5_1.

References

Martin N, Pardo J, Simmons M, Tjaden J, Widjaja S, Marovich M . An immunocytometric assay based on dengue infection via DC-SIGN permits rapid measurement of anti-dengue neutralizing antibodies. J Virol Methods. 2006; 134(1-2):74-85. DOI: 10.1016/j.jviromet.2005.12.002. View

Gentry M, Henchal E, McCown J, BRANDT W, Dalrymple J . Identification of distinct antigenic determinants on dengue-2 virus using monoclonal antibodies. Am J Trop Med Hyg. 1982; 31(3 Pt 1):548-55. DOI: 10.4269/ajtmh.1982.31.548. View

Rodrigo W, Alcena D, Rose R, Jin X, Schlesinger J . An automated Dengue virus microneutralization plaque assay performed in human Fc{gamma} receptor-expressing CV-1 cells. Am J Trop Med Hyg. 2009; 80(1):61-5. View

Endy T, Nisalak A, Chunsuttitwat S, Vaughn D, Green S, Ennis F . Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J Infect Dis. 2004; 189(6):990-1000. DOI: 10.1086/382280. View

Colbert J, Gordon A, Roxelin R, Silva S, Silva J, Rocha C . Ultrasound measurement of gallbladder wall thickening as a diagnostic test and prognostic indicator for severe dengue in pediatric patients. Pediatr Infect Dis J. 2007; 26(9):850-2. DOI: 10.1097/INF.0b013e3180619692. View

Ansarah-Sobrinho C, Nelson S, Jost C, Whitehead S, Pierson T . Temperature-dependent production of pseudoinfectious dengue reporter virus particles by complementation. Virology. 2008; 381(1):67-74. PMC: 3428711. DOI: 10.1016/j.virol.2008.08.021. View

RUSSELL P, Nisalak A . Dengue virus identification by the plaque reduction neutralization test. J Immunol. 1967; 99(2):291-6. View

Jones C, Patkar C, Kuhn R . Construction and applications of yellow fever virus replicons. Virology. 2005; 331(2):247-59. DOI: 10.1016/j.virol.2004.10.034. View

Pierson T, Diamond M, Ahmed A, Valentine L, Davis C, Samuel M . An infectious West Nile virus that expresses a GFP reporter gene. Virology. 2005; 334(1):28-40. DOI: 10.1016/j.virol.2005.01.021. View

10.

Henchal E, Putnak J . The dengue viruses. Clin Microbiol Rev. 1990; 3(4):376-96. PMC: 358169. DOI: 10.1128/CMR.3.4.376. View

11.

Pierson T, Sanchez M, Puffer B, Ahmed A, Geiss B, Valentine L . A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection. Virology. 2005; 346(1):53-65. DOI: 10.1016/j.virol.2005.10.030. View

12.

Mackenzie J, Gubler D, Petersen L . Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat Med. 2004; 10(12 Suppl):S98-109. DOI: 10.1038/nm1144. View

13.

Harvey T, Liu W, Wang X, Linedale R, Jacobs M, Davidson A . Tetracycline-inducible packaging cell line for production of flavivirus replicon particles. J Virol. 2003; 78(1):531-8. PMC: 303381. DOI: 10.1128/jvi.78.1.531-538.2004. View

14.

Harris E, Videa E, Perez L, Sandoval E, Tellez Y, Perez M . Clinical, epidemiologic, and virologic features of dengue in the 1998 epidemic in Nicaragua. Am J Trop Med Hyg. 2001; 63(1-2):5-11. DOI: 10.4269/ajtmh.2000.63.5. View

15.

Halstead S, Rojanasuphot S, Sangkawibha N . Original antigenic sin in dengue. Am J Trop Med Hyg. 1983; 32(1):154-6. DOI: 10.4269/ajtmh.1983.32.154. View

16.

Rocha C, Silva S, Gordon A, Hammond S, Elizondo D, Balmaseda A . Improvement in hospital indicators after changes in dengue case management in Nicaragua. Am J Trop Med Hyg. 2009; 81(2):287-92. View

17.

Halstead S, ORourke E . Antibody-enhanced dengue virus infection in primate leukocytes. Nature. 1977; 265(5596):739-41. DOI: 10.1038/265739a0. View

18.

Pohlmann S, Soilleux E, Baribaud F, Leslie G, Morris L, Trowsdale J . DC-SIGNR, a DC-SIGN homologue expressed in endothelial cells, binds to human and simian immunodeficiency viruses and activates infection in trans. Proc Natl Acad Sci U S A. 2001; 98(5):2670-5. PMC: 30196. DOI: 10.1073/pnas.051631398. View

19.

Tassaneetrithep B, Burgess T, Granelli-Piperno A, Trumpfheller C, Finke J, Sun W . DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J Exp Med. 2003; 197(7):823-9. PMC: 2193896. DOI: 10.1084/jem.20021840. View

20.

Davis C, Nguyen H, Hanna S, Sanchez M, Doms R, Pierson T . West Nile virus discriminates between DC-SIGN and DC-SIGNR for cellular attachment and infection. J Virol. 2006; 80(3):1290-301. PMC: 1346927. DOI: 10.1128/JVI.80.3.1290-1301.2006. View